Written by: Kayla Randle, PharmD, BCPS, BCOP, Kaiser Permanente Georgia Oncology
Download Here 

The purpose of this PQI is to identify differentiating characteristics which would indicate zanubrutinib (Brukinsa) as a preferred treatment option in Mantle Cell Lymphoma as well as discussing key counseling and monitoring criteria to improve patient outcomes.
Continue reading Zanubrutinib Patient Selection and Management in Mantle Cell Lymphoma

Read More

Written by: Alyson Leonard, PharmD, BCPS, BCOP, Cone Health
Download Here

Osimertinib is an indicated and preferred first line treatment option for patients with Epidermal Growth Factor Receptor (EGFR) gene mutation positive Non-Small Cell Lung Cancer (NSCLC) with Exon 19 deletion and exon 21 L858R.This PQI aims to provide guidance for initiating therapy with osimertinib. Continue reading Osimertinib (Tagrisso) in EGFR Positive NSCLC

Read More

JOHNS CREEK, Ga.

The Pharmacy Anti-Steering and Transparency Act, which will go into effect Jan. 1, 2020, prohibits insurers and benefits managers who have ownership in a pharmacy from steering patients to that business. The law endeavors to reduce conflicts of interests, increase transparency and give patients more choice.

The law was inspired in part by local pharmacist Jennifer Shannon, who saw first-hand how coercive steering practices can negatively impact patient care.

READ MORE

Read More